440 related articles for article (PubMed ID: 26688036)
1. Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations.
Korang-Yeboah M; Rahman Z; Shah D; Mohammad A; Wu S; Siddiqui A; Khan MA
Int J Pharm; 2016 Feb; 499(1-2):20-28. PubMed ID: 26688036
[TBL] [Abstract][Full Text] [Related]
2. Processing-induced phase transitions of theophylline--implications on the dissolution of theophylline tablets.
Tantry JS; Tank J; Suryanarayanan R
J Pharm Sci; 2007 May; 96(5):1434-44. PubMed ID: 17455350
[TBL] [Abstract][Full Text] [Related]
3. Real-time monitoring of changes of adsorbed and crystalline water contents in tablet formulation powder containing theophylline anhydrate at various temperatures during agitated granulation by near-infrared spectroscopy.
Otsuka M; Kanai Y; Hattori Y
J Pharm Sci; 2014 Sep; 103(9):2924-2936. PubMed ID: 24832393
[TBL] [Abstract][Full Text] [Related]
4. Spectroscopic-Based Chemometric Models for Quantifying Low Levels of Solid-State Transitions in Extended Release Theophylline Formulations.
Korang-Yeboah M; Rahman Z; Shah DA; Khan MA
J Pharm Sci; 2016 Jan; 105(1):97-105. PubMed ID: 26852844
[TBL] [Abstract][Full Text] [Related]
5. Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product.
Rahman Z; Korang-Yeboah M; Siddiqui A; Mohammad A; Khan MA
Int J Pharm; 2015 Nov; 495(1):19-30. PubMed ID: 26319638
[TBL] [Abstract][Full Text] [Related]
6. Dextrose monohydrate as a non-animal sourced alternative diluent in high shear wet granulation tablet formulations.
Mitra B; Wolfe C; Wu SJ
Drug Dev Ind Pharm; 2018 May; 44(5):817-828. PubMed ID: 29300107
[TBL] [Abstract][Full Text] [Related]
7. Manipulating theophylline monohydrate formation during high-shear wet granulation through improved understanding of the role of pharmaceutical excipients.
Wikström H; Carroll WJ; Taylor LS
Pharm Res; 2008 Apr; 25(4):923-35. PubMed ID: 17896097
[TBL] [Abstract][Full Text] [Related]
8. Zero-order release of aspirin, theophylline and atenolol in water from novel methylcellulose glutarate matrix tablets.
Khairuzzaman A; Ahmed SU; Savva M; Patel NK
Int J Pharm; 2006 Aug; 318(1-2):15-21. PubMed ID: 16621361
[TBL] [Abstract][Full Text] [Related]
9. Influence of processing-induced phase transformations on the dissolution of theophylline tablets.
Debnath S; Suryanarayanan R
AAPS PharmSciTech; 2004 Feb; 5(1):E8. PubMed ID: 15198529
[TBL] [Abstract][Full Text] [Related]
10. Chitosan and sodium sulfate as excipients in the preparation of prolonged release theophylline tablets.
Alsarra IA; El-Bagory I; Bayomi MA
Drug Dev Ind Pharm; 2005 May; 31(4-5):385-95. PubMed ID: 16093204
[TBL] [Abstract][Full Text] [Related]
11. Multi-unit dosage formulations of theophylline for controlled release applications.
Uhumwangho MU; Okor RS
Acta Pol Pharm; 2007; 64(6):553-9. PubMed ID: 18323251
[TBL] [Abstract][Full Text] [Related]
12. Effects of excipients on hydrate formation in wet masses containing theophylline.
Airaksinen S; Luukkonen P; Jørgensen A; Karjalainen M; Rantanen J; Yliruusi J
J Pharm Sci; 2003 Mar; 92(3):516-28. PubMed ID: 12587113
[TBL] [Abstract][Full Text] [Related]
13. Continuous twin screw granulation of controlled release formulations with various HPMC grades.
Vanhoorne V; Janssens L; Vercruysse J; De Beer T; Remon JP; Vervaet C
Int J Pharm; 2016 Sep; 511(2):1048-57. PubMed ID: 27521702
[TBL] [Abstract][Full Text] [Related]
14. Formulation and characterization of a compacted multiparticulate system for modified release of water-soluble drugs--Part II theophylline and cimetidine.
Cantor SL; Hoag SW; Augsburger LL
Drug Dev Ind Pharm; 2009 May; 35(5):568-82. PubMed ID: 18979306
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
[TBL] [Abstract][Full Text] [Related]
16. Predictive evaluation of pharmaceutical properties of direct compression tablets containing theophylline anhydrate during storage at high humidity by near-infrared spectroscopy.
Otsuka Y; Yamamoto M; Tanaka H; Otsuka M
Biomed Mater Eng; 2015; 25(3):223-36. PubMed ID: 26407109
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
[TBL] [Abstract][Full Text] [Related]
18. Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation.
Bayomi MA; Al-Suwayeh SA; El-Helw AR
Drug Dev Ind Pharm; 2001 Jul; 27(6):499-506. PubMed ID: 11548856
[TBL] [Abstract][Full Text] [Related]
19. Effects of liquisolid formulations on dissolution of naproxen.
Tiong N; Elkordy AA
Eur J Pharm Biopharm; 2009 Nov; 73(3):373-84. PubMed ID: 19679184
[TBL] [Abstract][Full Text] [Related]
20. Use of acryclic and metacrylic acid derivatives as sustained release matrices for theophylline hydrate tablets.
Ofoefule SI; Chukwu A
Boll Chim Farm; 1999 Nov; 138(10):526-30. PubMed ID: 10765469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
